About this trial
This observational cross-sectional study aims to assess retinal microvascular changes using optical coherence tomography angiography (OCTA) in patients with diabetic retinopathy. The study will evaluate retinal vessel density and foveal avascular zone parameters and investigate their correlation with best-corrected visual acuity and glycemic control (HbA1c) across different stages of diabetic retinopathy. The findings may improve understanding of retinal microvascular alterations and their clinical significance.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 18 to 80 years.
Patients diagnosed with diabetic retinopathy.
Ability to undergo complete ophthalmic examination including OCT and OCT angiography.
Availability of HbA1c measurement within the study period.
Disqualifiers
Previous vitreoretinal surgery.
Significant media opacity affecting image quality (e.g., dense cataract or vitreous hemorrhage).
Other retinal vascular diseases (e.g., retinal vein occlusion).
Glaucoma or optic nerve diseases affecting visual function.
Trial population
Adult patients (18-80 years) with diabetic retinopathy attending the Ophthalmology Department, Sohag University Hospital, who meet the eligibility criteria and undergo OCT angiography and complete ophthalmic examination.
Trial design
Cohort
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Retinal Microvascular Changes Measured by OCT Angiography
Assessment of retinal microvascular parameters including vessel density in the superficial and deep capillary plexuses and the foveal avascular zone (FAZ) using OCT angiography, and their correlation with best-corrected visual acuity and HbA1c.
Secondary outcomes
Correlation Between OCTA Parameters, Visual Acuity, and Glycemic Control
Evaluation of the association between OCTA-derived retinal microvascular parameters, best-corrected visual acuity, HbA1c level, and the stage of diabetic retinopathy.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.